Author Correction: Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation
Ananda S. Mirchandani(Centre for Inflammation Research), Sarah R. Walmsley(Centre for Inflammation Research), A. John Simpson(Newcastle University), Emily Watts(Centre for Inflammation Research), Manuel A. Sánchez-García(Queen's Medical Centre), Fiona Murphy(Queen's Medical Centre), David Griffith(Queen's Medical Centre), David H. Dockrell(University of Sheffield), Christos Spanos(University of Surrey), Anthony Rostron(Newcastle University), Van Kelly(Wellcome Centre for Cell Biology), Christopher W. Pugh(Nuffield Foundation), Liam Delaney(Queen's Medical Centre), Jürgen Schwarze(Queen's Medical Centre), Kathryn Musgrave(Newcastle upon Tyne Hospitals NHS Foundation Trust), Leila Reyes(Queen's Medical Centre), Pranvera Sadiku(University of Edinburgh), J. Kenneth Baillie(Roslin Institute), Clare Pridans(Centre for Inflammation Research), Tony Ly(University of Dundee), Nick Parkinson(Roslin Institute), I. Harper(Queen's Medical Centre), Hannah Lawson(University of London), Simone Arienti(Queen's Medical Centre), Kamil R. Kranc(Queen Mary University of London), Sarah J. Clark(University of Oxford), George Cooper(Queen's Medical Centre), Calum C. Bain(University of Glasgow), Stuart J. Forbes(MRC Centre for Regenerative Medicine), Tyler Morrison(Queen's Medical Centre), Peter J. Ratcliffe(The Francis Crick Institute), Sara Clohisey(Roslin Institute), Lara Campana(MRC Centre for Regenerative Medicine), Moira K. B. Whyte(University of Edinburgh), Patrícia Coelho(Queen's Medical Centre), David A. Lewis(University of Pittsburgh), Philip Starkey Lewis(MRC Centre for Regenerative Medicine), Nikhil Hirani(Centre for Inflammation Research), Rebecca Dickinson(Queen's Medical Centre), Stephen J. Jenkins(Roslin Institute), Jonathan Scott(Newcastle University), Ailiang Zhang(Soochow University)
Cited by 1
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
|Nature Immunology|2020|1.4k